Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
Westin
Johan
J
Hellstrand
Kristoffer
K
Alsiö
Asa
A
Ydreborg
Magdalena
M
Ferrari
Carlo
C
Neumann
Avidan U
AU
Pawlotsky
Jean-Michel
JM
Schalm
Solko W
SW
Zeuzem
Stefan
S
Verhey-Hart
Elke
E
Lagging
Martin
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a